Amgen's Repatha Cuts Death Risk in High-Risk Cardiovascular Patients
Event summary
- Amgen's Repatha reduced the risk of death by 20% in high-risk patients without prior heart attack or stroke in the VESALIUS-CV trial.
- The Phase 3 trial involved over 12,000 patients and showed benefits beginning after 1.5 years of treatment.
- Additional analyses showed Repatha reduced first, subsequent, and total cardiovascular events.
- Real-world studies highlighted undertreatment and disparities in lipid management, particularly among women.
The big picture
Amgen's latest data on Repatha reinforces the critical need for aggressive LDL-C lowering in high-risk cardiovascular patients. The findings come as cardiovascular disease remains the leading cause of death globally, highlighting the strategic importance of early intervention. Amgen's ability to leverage these results could strengthen its position in the cardiometabolic space, particularly as it develops additional therapies like maridebart cafraglutide (MariTide) and olpasiran.
What we're watching
- Market Adoption
- How quickly Repatha's expanded indication will be adopted in clinical practice, particularly for high-risk primary prevention patients.
- Competitive Dynamics
- Whether Amgen can sustain its leadership in the PCSK9 inhibitor space amid potential new entrants or therapeutic alternatives.
- Regulatory Impact
- The pace at which other regulatory bodies will approve Repatha's expanded use based on the VESALIUS-CV trial results.
Related topics